Stephanie H Hernandez, MD

Clinical Focus

• Toxicology

• Toxicology

Locations

Physician Office

1468 Madison Avenue, Agb MC 301, New York, NY, 10029

212-241-6794

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:7

Article:6

Review Article:2

Comment/Debate:1

Letter:2

Selected Publications

• Got milk? A case series of an amatoxin-exposed family, including a breastfeeding mother and infant
• Correction to: The Toxicology Investigators Consortium Case Registry—The 2017 Annual Report (Journal of Medical Toxicology, (2018), 14, 3, (182-211), 10.1007/s13181-018-0679-z)
• The Toxicology Investigators Consortium Case Registry—the 2016 Experience
• The Toxicology Investigators Consortium Case Registry—the 2015 Experience
• The pharmacokinetics and extracorporeal removal of N -acetylcysteine during renal replacement therapies
• Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage
• Safety and pharmacokinetics of oral Cannabidiol when administered concomitantly with intravenous Fentanyl in humans
• Prescription drug abuse: Insight into the epidemic
• N-butane canister foreign body
• Case Files of the New York City Poison Control Center: Paradichlorobenzene-Induced Leukoencephalopathy

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Hernandez did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.